Skip Navigation



eCAM Advance Access published online on July 28, 2004
eCAM, doi:10.1093/ecam/neh027
Copyright © 2004 by the Oxford University Press.
This Article
Right arrow Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
1/2/193    most recent
neh027v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Hsu, J.-H.
Right arrow Articles by Cheng, J.-T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hsu, J.-H.
Right arrow Articles by Cheng, J.-T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received January 19, 2004
Accepted April 21, 2004

Original Article

Mediation of Endogenous {beta}-endorphin by Tetrandrine to Lower Plasma Glucose in Streptozotocin-induced Diabetic Rats

Jen-Hao Hsu 1, Yang-Chang Wu 1, Shorong-Shii Liou 2, I-Min Liu 2, Lee-Wen Huang 3, Juei-Tang Cheng 3*

1 Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung City, Taiwan
2 Department of Pharmacy, Tajen Institute of Technology, Yen-Pou, Ping Tung Shien, Taiwan
3 Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan City, Taiwan

* To whom correspondence should be addressed. E-mail: jtcheng{at}mail.ncku.edu.tw.


  Abstract

The role of {beta}-endorphin in the plasma glucose-lowering action of tetrandrine in streptozotocin-induced diabetic rats (STZ-diabetic rats) was investigated. The plasma glucose concentration was assessed by the glucose oxidase method. The enzyme-linked immunosorbent assay was used to determine the plasma level of {beta}-endorphin-like immunoreactivity (BER). The mRNA levels of glucose transporter subtype 4 (GLUT4) in soleus muscle and phosphoenolpyruvate carboxykinase (PEPCK) in the liver of STZ-diabetic rats were detected by Northern blotting analysis. The expressed protein of GLUT4 or PEPCK was characterized by Western blotting analysis. Tetrandrine dose-dependently increased plasma BER in a manner parallel to the decrease of plasma glucose in STZ-diabetic rats. Moreover, the plasma glucose-lowering effect of tetrandrine was inhibited by naloxone and naloxonazine at doses sufficient to block opioid µ-receptors. Further, tetrandrine failed to produce plasma glucose-lowering action in opioid µ-receptor knockout diabetic mice. Bilateral adrenalectomy eliminated the plasma glucose-lowering effect and plasma BER-elevating effect of tetrandrine in STZ-diabetic rats. Both effects were abolished by treatment with hexamethonium or pentolinium at doses sufficient to block nicotinic receptors. Tetrandrine enhanced BER release directly from the isolated adrenal medulla of STZ-diabetic rats and this action was abolished by the blockade of nicotinic receptors. Repeated intravenous administration of tetrandrine (1.0 mg/kg) to STZ-diabetic rats for 3 days resulted in an increase in the mRNA and protein levels of the GLUT4 in soleus muscle, in addition to the lowering of plasma glucose. Similar treatment with tetrandrine reversed the elevated mRNA and protein levels of PEPCK in the liver of STZ-diabetic rats. The obtained results suggest that tetrandrine may induce the activation of nicotinic receptors in adrenal medulla to enhance the secretion of {beta}-endorphin, which could stimulate opioid µ-receptors to increase glucose utilization or/and reduce hepatic gluconeogenesis to lower plasma glucose levels in STZ-diabetic rats.

Keywords: tetrandrine; opioid µ-receptors; {beta}-endorphin; nicotinic receptors; glucose transporters subtype 4; phosphoenolpyruvate carboxykinase.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Evid Based Complement Alternat MedHome page
M. Bhat, S. K. Kothiwale, A. R. Tirmale, S. Y. Bhargava, and B. N. Joshi
Antidiabetic Properties of Azardiracta indica and Bougainvillea spectabilis: In Vivo Studies in Murine Diabetes Model
Evid. Based Complement. Altern. Med., April 23, 2009; (2009) nep033v1.
[Abstract] [Full Text] [PDF]

Home page
 Evid Based Complement Alternat MedHome page
G. Klein, J. Kim, K. Himmeldirk, Y. Cao, and X. Chen
Antidiabetes and Anti-obesity Activity of Lagerstroemia speciosa
Evid. Based Complement. Altern. Med., December 1, 2007; 4(4): 401 - 407.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.